ECSP10010723A - Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso - Google Patents

Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso

Info

Publication number
ECSP10010723A
ECSP10010723A EC2010010723A ECSP10010723A ECSP10010723A EC SP10010723 A ECSP10010723 A EC SP10010723A EC 2010010723 A EC2010010723 A EC 2010010723A EC SP10010723 A ECSP10010723 A EC SP10010723A EC SP10010723 A ECSP10010723 A EC SP10010723A
Authority
EC
Ecuador
Prior art keywords
multivally
meningococo
manufacturing
membrane vesicle
external membrane
Prior art date
Application number
EC2010010723A
Other languages
English (en)
Inventor
Wendell David Zoolinger
Mikhail Donets
Deborah Schmiel
Boris Ionin
Ryan Marques
Elizabeth Ellen Moram
Original Assignee
Us Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Army filed Critical Us Army
Publication of ECSP10010723A publication Critical patent/ECSP10010723A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente tecnología presenta una combinación de vesículas nativas de la membrana externa (NOMV) de por lo menos una cepa genéticamente modificada de la Neisseria que proporciona inmunidad protectora contra la enfermedad del meningococo, de preferencia la enfermedad del meningococo del subtipo B. La presente tecnología además presenta los métodos para la inmunización de un animal o un humano en contra de la enfermedad del meningococo que comprende la administración de la composición de la vacuna del presente invento
EC2010010723A 2008-05-30 2010-12-27 Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso ECSP10010723A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5746208P 2008-05-30 2008-05-30

Publications (1)

Publication Number Publication Date
ECSP10010723A true ECSP10010723A (es) 2011-05-31

Family

ID=41444870

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010723A ECSP10010723A (es) 2008-05-30 2010-12-27 Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso

Country Status (19)

Country Link
US (2) US9387239B2 (es)
EP (1) EP2296699A4 (es)
JP (2) JP5723768B2 (es)
KR (1) KR20110053314A (es)
CN (1) CN102105166A (es)
AU (1) AU2009262893B2 (es)
BR (1) BRPI0913268A2 (es)
CA (1) CA2726465A1 (es)
CO (1) CO6341569A2 (es)
CR (1) CR11812A (es)
DO (1) DOP2010000364A (es)
EC (1) ECSP10010723A (es)
IL (1) IL209660A0 (es)
MX (1) MX2010012999A (es)
NZ (1) NZ589812A (es)
RU (1) RU2477145C2 (es)
UA (1) UA99659C2 (es)
WO (1) WO2009158142A1 (es)
ZA (1) ZA201008548B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0010721A (pt) 1999-05-19 2002-06-11 Chiron Spa Composições de neisserias combinadas
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
JP2013521326A (ja) * 2010-03-10 2013-06-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
PL3831406T3 (pl) 2010-08-23 2024-09-09 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
RU2546873C2 (ru) 2010-09-10 2015-04-10 УАЙТ ЭлЭлСи Нелипидизированные варианты антигенов neisseria meningitidis orf2086
ES2759484T3 (es) 2010-09-10 2020-05-11 Glaxosmithkline Biologicals Sa Meningococo que sobreexpresa NadA y/o NHBA y vesículas de la membrana externa derivadas del mismo
GB201015132D0 (en) * 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
BR112014004606A2 (pt) 2011-08-31 2017-03-21 Children's Hospital & Res Center Oakland sequências modificadas geneticamente para facilitar a expressão de antígenos em neisseria e métodos de uso
BR112014019166A2 (pt) * 2012-02-02 2017-07-04 Novartis Ag promotores para expressão aumentada de proteína em meningococos
EP2823312B1 (en) 2012-03-08 2019-08-07 GlaxoSmithKline Biologicals SA In vitro potency assay for protein-based meningococcal vaccines
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY167723A (en) 2012-03-09 2018-09-21 Pfizer Neisseria meningitidis compositions and methods thereof
KR101452830B1 (ko) * 2012-04-06 2014-10-21 아이진 주식회사 두 가지 항암물질을 동시에 제공하는 대장균 균주
EP4056198A3 (en) 2012-09-18 2022-12-07 GlaxoSmithKline Biologicals SA Outer membrane vesicles
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
EP4098276A1 (en) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2017213129B2 (en) * 2016-01-28 2021-05-27 Intravacc B.V. Modified hexa-acylated neisserial LPS
EP3263695A1 (en) * 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Immunogenic compositions
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
LT3544637T (lt) * 2016-11-25 2021-03-25 Glaxosmithkline Biologicals S.A. Natyvių omv ir antigeno konjugatai bei jų naudojimo būdas
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
CN107151270B (zh) * 2017-03-22 2018-07-31 武汉博沃生物科技有限公司 重组ΔfHbp-NadA融合蛋白载体及其制备方法和应用
BR112021018694A2 (pt) 2019-03-21 2021-11-30 Codiak Biosciences Inc Vesículas extracelulares para distribuição de vacina
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN113151354B (zh) * 2021-03-22 2022-03-08 中国农业科学院兰州兽医研究所 一种用于条件性敲除目的基因的载体及条件性敲除目的基因的方法
IT202400003229A1 (it) 2024-02-15 2025-08-15 Cioccio Vito Di Procedimento per la purificazione di omv da batteri gram-negativi, e relativi usi
CN119020251A (zh) * 2024-08-26 2024-11-26 南昌大学 一株脂多糖修饰b群脑膜炎球菌与其外膜囊泡制备及应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4601903A (en) * 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US7118757B1 (en) * 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
WO1990006696A2 (en) 1988-12-19 1990-06-28 Praxis Biologics, Inc. Meningococcal class 1 outer-membrane protein vaccine
DE4023721A1 (de) 1990-07-26 1992-01-30 Boehringer Mannheim Gmbh Verfahren zur herstellung von vakzinen und ihre verwendung
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
NL9201716A (nl) * 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
US7112332B1 (en) * 1992-10-08 2006-09-26 The United States Of America As Represented By The Secretary Of The Army Oral or intranasal vaccines using hydrophobic complexes having proteosomes and lipopolysaccharides
DE69423383T2 (de) * 1993-05-13 2000-08-24 American Cyanamid Co., Wayne Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
CN1211192A (zh) * 1995-09-18 1999-03-17 美国陆军医疗材料研究指挥部 生产非共价复合的多价蛋白体亚基疫苗的改进方法
US6558677B2 (en) * 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
GB9808866D0 (en) 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
US20030215469A1 (en) * 1998-11-02 2003-11-20 Microbiological Research Authority Multicomponent meningococcal vaccine
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
ATE386541T1 (de) 1999-02-22 2008-03-15 Health Prot Agency Neisseria impfstoffzusammensetzungen und methoden
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
CA2871789C (en) * 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
OA12302A (en) * 2000-06-29 2003-10-24 Glaxosmithkline Biolog Sa Multivalent vaccine composition.
GB0103170D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
GB0103169D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
WO2002080648A2 (en) * 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
EP1374892A1 (en) * 2002-06-28 2004-01-02 Braun, Jan Matthias, Dr. Medicament for the treatment of diseases due to infection by Neisseria Meningitidis
DE20321889U1 (de) 2002-08-02 2012-03-12 Glaxosmithkline Biologicals S.A. Impfstoffzusammensetzung
CU23377A1 (es) 2003-11-04 2009-05-28 Ct De Ingenieria Genetica Y Biotecnologia Metodo para la incorporacion de antigenos en vesiculas de membrana externa de bacterias y formulaciones resultantes
JP5173194B2 (ja) * 2003-12-23 2013-03-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
WO2005107798A1 (en) * 2004-05-11 2005-11-17 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Vws NEISSERIA MENINGITIDIS IgtB LOS AS ADJUVANT
US7537766B2 (en) * 2004-08-30 2009-05-26 Wyeth Neisseria meningitidis inner core lipo-oligosaccharide epitopes, multivalent conjugates thereof and immunogenic compositions thereof
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
SI2682126T1 (sl) * 2005-01-27 2017-03-31 Children's Hospital & Research Center At Oakland Cepiva na osnovi veziklov, osnovanih na GNA1870, za širokospektralno zaščito proti boleznim, povzročenim z Neisserio meningitidisom
EP2032161B1 (en) * 2006-06-12 2012-07-11 GlaxoSmithKline Biologicals S.A. L3v los vaccines

Also Published As

Publication number Publication date
MX2010012999A (es) 2012-03-07
JP2011521976A (ja) 2011-07-28
US20170100471A1 (en) 2017-04-13
AU2009262893A1 (en) 2009-12-30
RU2477145C2 (ru) 2013-03-10
UA99659C2 (uk) 2012-09-10
DOP2010000364A (es) 2011-07-15
NZ589812A (en) 2012-08-31
US20110182942A1 (en) 2011-07-28
CN102105166A (zh) 2011-06-22
CR11812A (es) 2011-07-06
IL209660A0 (en) 2011-02-28
AU2009262893B2 (en) 2015-05-21
CA2726465A1 (en) 2009-12-30
RU2010153658A (ru) 2012-08-10
JP2015061870A (ja) 2015-04-02
BRPI0913268A2 (pt) 2016-03-15
CO6341569A2 (es) 2011-11-21
US9387239B2 (en) 2016-07-12
KR20110053314A (ko) 2011-05-20
WO2009158142A1 (en) 2009-12-30
ZA201008548B (en) 2012-06-27
JP5723768B2 (ja) 2015-05-27
EP2296699A1 (en) 2011-03-23
EP2296699A4 (en) 2013-11-13
AU2009262893A9 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
ECSP10010723A (es) Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso
AR064009A1 (es) Metodo de inmunizacion contra los 4 serotipos del dengue
AR118199A2 (es) Composiciones inmunogénicas de variantes no lipidadas no piruviladas de antígenos orf2086 de neisseria meningitidis, polipéptidos, secuencias de nucleótidos y plásmidos
CR11122A (es) Vacuna de influenza de emulsion de aceite en agua
NO20090062L (no) Influensavaksine
AR078247A1 (es) Vacuna de pcsk9
ES2585810T3 (es) Uso de un virus de la gripe y un adyuvante de emulsión de aceite en agua para inducir respuesta de células T CD4 y/o una respuesta de células B de memoria mejorada
CL2011000513A1 (es) Metodos para reducir o inhibir la angiogenesis en un sujeto que tiene una enfermedad o condicion ocular asociada con la angiogenesis que comprende la administracion de un antagonista de tetraspanina 12(tspan12) y/o un antagonista de norrina.
BRPI0607374A2 (pt) vacinas de vesìculas baseadas em gna1870 para proteção de amplo espectro contra doenças causadas por neisseria meningitidis
MY169275A (en) Method of immunization against the four serotypes of dengue
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
BR112014031386A2 (pt) vacinas para meningococos do sorogrupo x
PE20151588A1 (es) Vacuna contra el virus del dengue
CA2763359C (en) New human rotavirus strains and vaccines
CL2017001961A1 (es) Vacuna bivalente contra el virus de gripe porcina
UA114286C2 (uk) Спосіб лікування staphylococcus aureus
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
MX390304B (es) Proceso para preparar una vacuna tetravalente atenuada contra el dengue.
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
MX2017013564A (es) Formulaciones de glucopiranosil lipido a y alérgenos de cacahuete para administración sublingual.
WO2010039924A3 (en) Th1 vaccination priming for active immunotheraphy
ECSP12011951A (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria
AR065765A1 (es) Composicion de vacuna para el tratamiento de enfermedades infecciosas respiratorias
AR087811A1 (es) Vacuna contra el staphylococcus aureus